[1] | Bastaki. S, 2005, Diabetes mellitus and its treatment. Int J Diabetes and Metabolism, 13: 111-134. |
[2] | Groop. L, 2000, Genetics of the metabolic syndrome, Br J Nutr, 83: 39-48. |
[3] | Ho. SC, Chen. YM, Woo. JL, Leung. SS, Lam. TH, Janus. ED, 2001, Association between simple anthropometric indices and cardiovascular risk factors, Int J Obes Relat Metab Disord, 25: 1689-1697. |
[4] | Ascaso. JF, Romero. P, Real. JT, Lorente. RI, Martinez-Valls. J, Carmena. R, 2003, Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population. Eur J Intern Med. 14: 101-106. |
[5] | Chan. JM, Rimm. EB, Colditz. GA, Stampfer. MJ, Willett. WC, 1994, Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men, Diabetes Care, 17: 961-969. |
[6] | Goldfine. AB, Kulkarni. RN, 2012, Modulation of beta-cell function: a translational journey from the bench to the bedside. Diabetes Obes Metab, 3:152- 60. |
[7] | Lau. DC, Dhillon. B, Yan. H, Szmitko. PE, Verma. S, 2005, Am. J. Physiol. Heart. Circ. Physiol, 288: 2031-41. |
[8] | Fagerberg. B, Kellis. D, Bergstrom. G, Behre. CJ, 2011. Adiponectin in relation to insulin sensitivity and insulin secretion in the development of type 2 diabetes: a prospective study in 64-year-old women. J. Int. Med, 269: 636–643. |
[9] | American Diabetes Association, 2005, Diagnosis and classification of diabetes mellitus, Diabetes Care, 28: 37-42. |
[10] | Ginsberg. HN, 2006, REVIEW, Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia, J Clin Endocrinol Metab, 91: 383-392. |
[11] | Nourmohammadi. I, Shalmani. IK, Shaabani. M, Gohari. L, 2000, Zinc, copper, chromium, manganese and magnesium levels in serum and hair of insulin-dependent diabetics. Arch Iranian Med 2000; 2:88-100. |
[12] | Candilish DJ. Minerals. J Am Coll Nutr, 17:286-310. |
[13] | Trinder. P, 1969, Determination of glucose in blood using glucose oxidase with an alternative oxygen receptor, Ann. Clin. Biochem. 6, 24-27. |
[14] | Kumar. S, Malhotra. R, Kumar. D, 2010, Antidiabetic and free radicals scavenging potential of Euphorbia hirta Flower Extract, Ind. J. Pharm. Sci., 72: 533-537. DOI: 10.4103/0250-474X.73921 |
[15] | Freidewald. WT, Levy. RI, Frederickson. DS, 1972, Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge, Clin. Chem., 18: 499-502. www.clinchem.org/content/18/6/499.short |
[16] | Judzewitsch. RG, Pfeifer. MA, Best. JD, Beard. JC, Helter. JB, Porte. DJ, 1982, Chronic Chlorpropamide therapy of noninsulin-dependent augments basal and stimulated insulin secretion islet sensitivity to glucose, J.Clin. End. Metab., 55(2): 321-328. |
[17] | Yalow. RS, Berson. SA, 1971, Principles of Competitive Protein-Binding Assays (Odell. WD, Daughaday. WH, eds.), Lippincott, Philadelphia, pp: l-21. |
[18] | Tietz. NW, 1995, Clinical Guide to laboratory tests, 3rd ed. W.B. Saunders, Philadephia. pp: 578-580. |
[19] | Al-Fartosy. AJM, Shanan. SK, Awad. NA, 2017, Biochemical Study of the Effects of Some Heavy Metals on Oxidant / Antioxidant Status in Gasoline Station Workers /Basra-Iraq, Inter. J. Sci. Rese. Public., 7(2): 83-94. |
[20] | Ji. X, Ren. J, 2002, Determination of copper and zinc in serum by Derivation atomic absorption spectrometry using the micro sampling technique, Analyst, 127, pp: 416-419. |
[21] | Carmena. R, 2008, High risk of lipoprotein dysfunction in type 2 diabetes mellitus. Rev Esp Cardiol Supl., 8: 18-24. |
[22] | Beck-Nielsen. H, Hother-Nielsen. O, 2004, Obesity in type 2 diabetes mellitus. In LeRoith. D, Taylor. SI, Olefsky. JM, editors; Diabetes Mellitus: A Fundamental and Clinical Text. 3rd edition, Lippincott Williams & Wilkins, Philadelphia, PP: 858-869. |
[23] | Phillips. C, Owens. D, Collins. P, Tomkin. GH, 2002, Microsomal triglyceride transfer protein: does insulin resistance play a role in the regulation of chylomicron assembly, Atherosclerosis, 160: 355–360. |
[24] | DeFronzo. RA, 1988, The triumvirate: beta cell, muscle, liver a collusion responsible for NIDDM, Diabetes, 37: 667-687. |
[25] | Del Prato. S, Bonadonna. R C, Bosom. E, 1993, Characterization cellular defects of insulin action in type2 (noninsulin dependent) diabetes mellitus. Int. Clinin. vest., 91:4-494. |
[26] | Richard. M B, Cdemargaret. AP, Alan. W., Aleksandra. V, Priscilla. H, Marc. R, 2008, Adjust to Target in Type 2 Diabetes. Comparison of a simple algorithm with carbohydrate counting for Adjustment of mealtime insulin glulisine, Diabetes Care, 31: 1305-1310. |
[27] | Pari. L, Latha. M, 2002, Effect of Cassia auriculata flowers on blood sugar levels, serum and tissue lipids in streptozotocin diabetic rats, Singapore Med. J, 43: 617-622. |
[28] | McGarry. JD, 2002, Dysregulation of fatty acid metabolism in the etiology of Type 2 diabetes, Diabetes, 51: 7-18. |
[29] | Fruchart. JC, Sacks. F, Hermans. MP, 2008, The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia, Amer. J. Cardiol, 102: 1-34. |
[30] | Poitout. V, Robertson. RP, 2002, Minireview: Secondary β-cell failure in Type 2 diabetes- a convergence of glucotoxicity and lipotoxicity, Endocrinology, 143(2): 339-342. |
[31] | Colhoun. HM, Betteridge. DJ, Durrington. PN, 2004, Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial, Lancet, 36(4): 685-696. |
[32] | Mavrakanas. T, Frachebois. C, Soualah. A, Aloui. F, Julier. I, Bastide. D, 2009, C-peptide and chronic complications in patients with type 2 diabetes and the metabolic syndrome, Presse Med, 38:1399-1403. |
[33] | Son. SM, 2012, C-peptide and vascular complications in type 2 diabetic Subjects, Diabetes Metab J, 36: 345-349. |
[34] | Gadre. S, Bajaj. A, Patil. SS, Sukumaran. S, 2015, C-peptide and its correlation to parameters of insulin resistance and obesity in type 2 diabetes, Indian Journal of Basic and Applied Medical Research, 5(1): 285-291. |
[35] | Lawlor. DA, Smith. DG, Ebrahim. S, Thompson. C, Sattar. N, 2005, Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women, J Clin Endocrinol Metab, 90:5677-5683. |
[36] | Li. S, Shin. JJ, Ding. EL, Dam. RM, 2009, Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis, The Journal of the American Medical Association, 302(2): 179-188. |
[37] | Kadowaki. T, Yamauchi. T, Kubota. N, Hara. K, Ueki. K, Tobe. K, 2006, Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome, J. Clin. Invest, 116 (7): 1784-1792. |
[38] | Combs. TP, Berg. AH, Obici. S, Scherer. PE, Rossetti. L, 2001, Endogenous glucose production is inhibited by the adipose-derived protein Acrp30, J Clin Invest, 108: 1875-1881. |
[39] | Yamauchi. T, Kamon. J, Ito. Y, Tsuchida. A, Yokomizo. T, Kita. S, Sugiyama. T, Miyagishi. M, Hara. K, Tsunoda. M, Murakami. K, Ohteki. T, Uchida. S, Takekawa. S, Waki. H, Tsuno. NH, Shibata. Y, Terauchi. Y, Froguel. P, Tobe. K, Koyasu. S, Taira. K, Kitamura. T, Shimizu. T, Nagai. R, Kadowaki. T, 2003, Cloning of adiponectin receptors that mediate antidiabetic metabolic effects, Nature, 423(6941): 762-769. |
[40] | Lara-Castro. C, Luo. N, Wallace. P, Klein. RL, Garvey. WT, 2006, Adiponectin multimeric complexes and the metabolic syndrome trait cluster, Diabetes, 55: 249-259. |
[41] | Chen. MB, McAinch. AJ, Macaulay. SL, Castelli. LA, O’Brien. PE, Dixon. JB, Cameron-Smith. D, Kemp. BE, Steinberg. GR, 2005, Impaired activation of AMP-kinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle of obese type 2 diabetics, J. Clin. Endocrinol. Metab, 90: 3665-3672. |
[42] | Mao. X, Kikani. CK, Riojas. RA, Langlais. P, Wang. L, Ramos. FJ, Fang. Q, Christ-Roberts. CY, Hong. JY, Kim. RY, Liu. F, Dong. LQ, 2006, APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function, Nat Cell Biol, 8(5): 516-523. |
[43] | Bottner. A, Kratzsch. J, Muller. G, Kapellen. TM, Bluher. S, Keller. E, Kiess. W, 2004, Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels, J. Clin. Endocrinol. Metab, 89: 4053-4061. |
[44] | Cnop. M, Havel. PJ, Utzschneider. KM, Carr. DB, Sinha. MK, Boyko. EJ, Kahn. SE, 2003, Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex, Diabetologia, 46: 459-469. |
[45] | Mooradian. AD, 2009, Dyslipidemia in type 2 diabetes mellitus. Nature clinical practice Endocrinology and metabolism, 5(3): 15-19. |
[46] | Sniderman. AD, Scantlebury. T, Cianfione. K, 2001, Hypertriglyceridaemic hyperpob: the unappreciated atherogenic dyslipidaemia in type 2 diabetes mellitus, Ann. Intern. Med., 135: 447-459. |
[47] | Gowri. MS, Vander Westhuyzen. DR, Bridges. SR, Anderson. JW, 1999, Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL, Arterioscler Thromb Vasc Biol, 19: 2226-2233. |
[48] | Isezuo. SA, Badung. SLH, Aimls. F, Omotoso. ABO, Nigeria. I, 2003, Comparative analysis of lipid profiles among Patients with type 2 diabetes mellitus, Hypertension and concurrent type 2 diabetes, and hypertension: A view of metabolic syndrome, Journal of the national medical association, 95(5): 328-334. |
[49] | Barrett-Connor. E, Wingard. DL, 1983, Sex differential in ischemic heart disease mortality in diabetics: a prospective population-based study. Amer. J. Epidem., 118(4): 489-96. |
[50] | Gordon. L, Ragoobirsingh. D, St Errol. Y, Choo-Kang. E, McGrowder. D, Martorell. E, 2010, Lipid profile of type 2 diabetic and hypertensive patients in the Jamaican population, J. Labor. Physic., 2(1): 25-30. |
[51] | Krentz. AJ, 2003, Lipoprotein abnormalities and their consequences for patients with type 2 diabetes, Diabetes, Obesity and Metabolism, 5(1): 19-27. |
[52] | Vergès. B, 2015, Pathophysiology of diabetic dyslipidaemia: where are we, Diabetologia, 2015: 1-14. |
[53] | Rahbni-Nobar. ME, Rahimi-Pour. A, Rahbani-Nobar. M, Adi-beig. F, Mirha shemim. SM, 1999, Total antioxidant capacity, superoxide dismutase and glutathione peroxidase in diabetic patients, Med. J. Inslamic Acad. Scie., 12(4): 109-114. |
[54] | Ginsbery. HN, 1996, Diabetic dyslipidaemia, basic mechanisms underlying the common hypertriglyceridaemia and low HDL cholesterol levels, Diabetes, 45(3): 27-30. |
[55] | Krauss. RM, Siri. PW, 2004, Metabolic abnormalities: triglyceride and low-density lipoprotein, Endocr. Met. Clin. Nort. Am., 33: 405-415. |
[56] | Schwartz. GG, Reis. IM, 2000, Is cadmium a cause of human pancreatic cancer, Cancer Epidemiol. Biomarkers Prev, 9: 139-145. |
[57] | Evans. JL, Maddux. BA, Goldfine. ID, 2005, The molecular basis for oxidative stress-induced insulin resistance, Antioxid Redox Signal, 7: 1040-1052. |
[58] | Li. YV, 2014, Zinc and insulin in pancreatic beta-cells, Endocrine, 45: 178-189. |
[59] | Masood. N, Baloch. GH, Ghori. RA, Memon. IA, Memon. MA, Memon. MS, 2009, Serum Zinc and Magnesium in Type-2 Diabetic Patients, J. Coll. Phys. Surg. Pakist., 19(8): 483-486. |
[60] | Al-Fartosy. AJM, Awad. NA, Zearah. SA, 2011, Assessment the effect of Zn and Mg supplementation on total antioxidant capacity in type 2 diabetic patients, Basrah Journal of SCience, 28(1): 94-100. |
[61] | Duzguner. V, Kaya. S, 2007, Effect of zinc on the lipid peroxidation and the antioxidant defense systems of the alloxan-induced diabetic rabbits, Inter. J. Free Rad. Biol. Med., 42: 1481-6. |
[62] | Myers. SA, Nield. A, Myers. M, 2012, J. Nutr. Metabol., 12(6): 17-37. |
[63] | Jansen. J, Karges. W, Rink. L, 2009, J. Nutr. Biochem., 20(6): 399-417. |
[64] | Khan. FA, Khan MF, et al., 2013, Estimation of serum copper and magnesium levels in diabetic nephropathy patients, Asian J. Biol. Life Sci., 2(1): 23-26. |
[65] | Nasri. H, Baradaran. HR, 2008, Lipids in association with serum magnesium in diabetes mellitus patients, Bratisl Lek Listy, 109(7): 302-306. |